Parathyroid hormone as a therapeutic agent
B. Mitlak(Eli Lilly (United States))
Cited by 20
Related Papers
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy
|Osteoporosis International|2004|320
Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting
|Osteoporosis International|2008|103
The effect of 2 and 3 years of Raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis
|ORBi (University of Liège)|1998|21
Raloxifene therapy for 3 years reduces the risk of incident vertebral fractures in postmenopausal women
|ORBi (University of Liège)|1999|4
Effects of arzoxifene on fracture incidence in postmenopausal women with osteoporosis or with low bone mass
|ORBi (University of Liège)|2010|2